Premium
END OF TREATMENT PET‐CT PREDICTS PROGRESSION‐FREE SURVIVAL IN DLBCL AFTER FIRST‐LINE TREATMENT: RESULTS FROM THE PHASE III GOYA STUDY
Author(s) -
Kostakoglu L.,
Martelli M.,
Belada D.,
Carella A.M.,
Chua N.,
GonzalezBarca E.,
Hong X.,
Pinto A.,
Sehn L.H.,
Shi Y.,
Tatsumi Y.,
FingerleRowson G.,
Mattiello F.,
Nielsen T.,
Sahin D.,
Vitolo U.,
Trněný M.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_45
Subject(s) - medicine , nuclear medicine , clinical endpoint , rituximab , pet ct , diffuse large b cell lymphoma , progression free survival , chop , phases of clinical research , oncology , clinical trial , positron emission tomography , lymphoma , overall survival